Hematology

Athersys has made progress in enrollment with its MATRICS-1 and MASTERS-2 clinical trials.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The clinician scientist at St. Jude Children’s Research Hospital discussed the session on cell therapies in acute leukemias and Hodgkin lymphoma she moderated at ASH 2022.

The assistant member at St. Jude Children’s Research Hospital discussed the ASH 2022 basic and translational science session she moderated.

The new analysis data was requested by the FDA ahead of the therapy’s March 31, 2023 PDUFA date.

Brent Warner, president, gene therapy, Poseida Therapeutics, discussed data on the preclinical P-FVIII-101 presented at ASH 2022.

CKO804 is being evaluated as an add-on therapy to ruxolitinib in patients whose disease had a suboptimal response to ruxolitinib alone.

The first patient dosed in the study experienced a case of prolonged pancytopenia that has required ongoing transfusion and growth factor support.

Review top news and interview highlights from the week ending January 6, 2023.

Ying Huang, chief executive officer, Legend Biotech, discussed new data from the CARTIFAN-1 and CARTITUDE-2 studies.

Allocetra previously demonstrated efficacy in a phase 1b trial for patients with sepsis.

The associate professor of medicine from University of Pennsylvania discussed updated data on huCART19-IL18 presented at the ASH 2022 meeting.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CT103A is currently being evaluated in multiple clinical trials in China.

The assistant member at St. Jude Children’s Research Hospital discussed updated data from a phase 1 study being conducted at the hospital.

The BALLI-01 study, initiated in 2019, has now dosed its first patient with an in-house manufactured CAR T-cell therapy candidate.

The company is seeking out other companies to continue development of its autologous CAR-T platform.

Updated data were presented at the ASH 2022 annual meeting.

The first year after treatment yielded statistically significant improvements in overall QOL and symptoms within the first year of treatment for relapsed/refractory large B-cell lymphoma

Second-line lisocabtagene maraleucel reduced the risk of an event occurring by 64.4% compared with standard-of-care chemoimmunotherapy induction and autologous stem cell transplantation.

Review some of our most-viewed coverage of advancements in cell therapies, including study data and clinical trial updates.

Annualized bleeding rates were superior with the gene therapy fidanacogene elaparvovec compared with factor IX treatment for patients with moderately severe to severe hemophilia B.

The CR was achieved at 1-month post-treatment.

Review some of our most-viewed coverage of advancements in gene therapies, including study data and clinical trial updates.

Review some of our most-viewed interviews with clinicians, researchers, and biotech companies about expanding applications of cell and gene therapies.